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Objective. To evaluate if radiotherapy planning with 18F-FDG PET/CT in rectal cancer (RC) can modify the gross tumor volume
(GTV) to be irradiated compared to pelvic MRI. In addition, if PET/CT provides additional information on initial staging of RC.
Materials and methods. We retrospectively analysed 39 patients (23 male, mean age 68 years) with RC, who had a PET/CT scan
performed for radiotherapy planning and an MRI with an interval of time not exceeding 30 days. GTV in both studies (PET/CT
and MRI) included: (a) primary rectal tumor and (b) pelvic lymph nodes or perirectal soft tissue injuries increased in size, usually
larger than 1 cm. The GTV determined by PET/CT measure also included subcentimetric lymph nodes with pathological 18F-FDG
uptake (SUVmax >2.5).
Results. In 23/29 (59%) patients PET/CT did not induce changes in the GTV. In 7/39 (18%) PET/CT underestimated the GTV (MRI
showed millimetric lymphadenopaties in mesorectum suggestive of malignancy, while PET/CT did not reveal pathological uptake
of 18F-FDG in this location, probably due to the small size of these lymph nodes. In 7/39 (18%) PET/CT modiﬁed the GTV (GTV
increased in 6 patients and decreased only in one). In the two remaining patients (5%) GTV was not deﬁned as PET/CT detected
liver metastases and neoadjuvant chemotherapy was initiated because the patients were asymptomatic locally. PET/CT also
identiﬁed distant metastases in 14 patients, unknown in 8 of them (21%), inducing a different therapeutic management (in 4
patients surgical liver metastases resection was performed, in one patient the lung disease was totally resected and in three
patients the chemoradiotherapeutic treatment was modiﬁed.
Conclusion. The combination of the information supplied by PET/TC and MRI is useful in the precise deﬁnition of GTV in rectal
cancer, minimizing normal tissues radiation. Unknown metastases detected in PET/TC can modify patient management in
these cases.
http://dx.doi.org/10.1016/j.rpor.2013.03.193
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Objetives. The aim of this retrospective analysis was to determinate efﬁcacy, safety and feasibility of conservative treatment with
radiochemotherapy (CRCT) of patients with anal canal cancer referred to our service.
Patients and methods. Between February 2002 and April 2012, 19 patients with anal canal cancer were treated with radical CRCT.
The treatment schedule consisted of 3D conformal external radiotherapy or IMRT (prophylactic pelvic nodal: 45Gy and gross
disease: 60.4Gy) with concurrent chemotherapy (Mitomycin C and 5-FU or CDDP and 5-FU).
Results. Median age was 65 years (35–83). Gender: male 57.9%, female 42.1%. 36.8% were HIV positive. Staging of the cancer was
as follows: T2-T3N0 47.4% and N2–N3 52.6%. The RT treatment was completed by 84.2% patients and 15.8% was suspended for
digestive and cutaneous toxicity; 78.9% patients received QT (9 scheme with 5-FU and mitomycin and 6 with cisplatin and 5-FU).
With a median of follow-up of 21 months (range 3–87 months), OS at 2 and 5 years was of 67% and 34% respectively. The DFS at
2 and 5 years was 67% and 30% respectively. Cause-speciﬁc survival was at 2 and 5 years 74% and 51% respectively. Colostomy
free survival at 2 and 5 years was 77%. CRCT resulted in grade 3 mucocutaneous toxicity in 42% of patients. No cases of grade
4 toxicity were observed. There was no difference in the analysis based on age, sex, HIV status or QT scheme used.Conclusion.
Conservative treatment with radiochemotherapy offers high rates of colostomy free interval. The toxicity of the treatment is
high but admissible. Data on OS and DFS are similar to those published in the literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.194
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Introduction. Gastric cancer usually recurs in the ﬁrst 5 years after initial treatment, affecting peritoneum, local lymph nodes
or liver. Bone metastasis are very rare (0.99–2.1%), but are described cases of ﬁrst symptom onset of spread, many years after
surgery.
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Materials and methods. Two patients diagnosed and treated for gastric cancer 4 and 20 years before the onset of bone metastasis.
Both are man of 57 and 47 years old. In both cases the metastasis were multiple and initial clinical was spinal cord compression
(D11-L1 and D4), both operated (laminectomy and ﬁxation of fracture). Gastric origin was found on histology. Both these locations
receive radiotherapy after surgery (20Gy in 5 sessions) followed by chemotherapy.
Results and conclusion. Treatment outcome in both cases was wrong, not correct the neurological clinical and with short survival.
This presentation is described in young patients with a history of gastric cancer generally undifferentiated tumors with positive
nodes and types III and IV of Borrman. Usually are osteolytic metastases, but also there are described osteoblasts. Cases have
been reported after 4, 11 and 19 years of initial treatment and our 20 years is the furthest from the primary we know. Is some-
times associated with bone marrow involvement and disseminated intravascular coagulation (DIC). The prognosis is poor in the
short/medium term.
http://dx.doi.org/10.1016/j.rpor.2013.03.195
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Objectives. To investigate dosimetric predictors of Grade 3 or greater gastrointestinal (GI) toxicity during hypofractionated
intensity-modulated radiation therapy concomitant with capecitabine and oxaliplatin (IMRT-CAPOX) in patients with locally
advanced rectal cancer (LARC).
Patients and methods. Patients with diagnostic of T3–T4 and/or N0–N+ rectal cancer received Capecitabine 825mg/m2 twice
daily Monday through Friday and oxaliplatin 60mg/m2 intravenously on Days 1, 8, and 15, concurrently with IMRT
(47.5Gy/2.5Gy/fraction/20 fractions). All patients who underwent IMRT-CAPOX from March 2003 to July 2008 were analyzed.
Dose volume histograms (DVH) of the small bowel (SB), rectum and sphincter were individually recovered. Correlation between
dosimetric parameters (V5, V10, V15, V20, V25, V30, V35, V40, V45, V50, V55) from each organ and Grade 3 GI toxicity (diarrhea
and rectitis) was investigated using logistic regression. Best predictive cut-off values were assessed by ROC curves.
Results. 100 patients were analyzed. No Grade 4 toxicity was assessed. Grade 3 diarrhea was observed in 9 patients (9%), and
grade 3 rectitis in 11 patients (11%). No dose-volume predictors related to Grade 3 rectitis were found. V10, V15 and V50 of SB
were found to be dose-volume predictors of G3 diarrhea (p=0.01, p=0.02 and p=0.027, respectively) and the best cut-off value
for each volume was 92.6 cm3, 78.8 cm3 and 4.44 cm3 respectively.
Conclusion. Low doses to high volumes of SB, such a V10 and V15, seem to be predictors of G3 diarrhea in LARC patients treated
with hypofractionated IMRT-CAPOX protocol. We are currently using these constraints in our LARC patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.196
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Resumen
Background and aim. Neoadjuvant treatment with concurrent radiochemotherapy improves local control in locally advanced
rectal cancer, however its effect on survival outcomes is still controversial. In order to determinate the impact on survival of this
modality of treatment we have evaluated the correlation between the tumour response after preoperative treatment and survival
beneﬁt. Methods: We have reviewed the data from 108 patients with locally advanced rectal cancer (T3–4 N0 M0/Tx N1–2 M0). All
patients were treated preoperatively with concurrent radiotherapy and either raltitrexed (3mg/m2 days 1, 19, 38) or capecitabine
(825mg/m2 twice daily on days 1–38) based chemotherapy regimen. pTNM staging was evaluated in both regimens and tumour
regression grade (TRG) was measured using Dworak system that goes from TRG 0 to TRG 4 (complete regression).
Results. Tumour regression grade as follows: TRG 4, 6 patients (6.1%); TRG 3, 15 patients (15.3%); TRG 2, 57 patients (58,2%); TRG 1,
20 patients (20.4%). Down-staging after preoperatively treatment: 57 patients (58.2%). Signiﬁcant correlation was found between
tumour regression grade and survival, either overall and disease-free survival. Five-year disease-free survival was 100, 89.9, 66.7
and 33% in TRG 4, 3, 2, and 1, respectively (p<0.001). Five-year overall survival was 83.3, 89.9, 82.3 and 49.7%, respectively, in TRG
4, 3, 2 and 1 (p<0.001). Five-year cancer-speciﬁc survival was 100, 100, 78 and 44% in TRG 4, 3, 2 and 1, respectively.
